Hydroxychloroquine Sulfate (Plaquenil): A Possible Candidate for Pandemic SARS-CoV-2 or (COVID-19) ?

(E-pub Ahead of Print)

Author(s): Subhash Chandra*, Sarla Saklani, Hassan Y. Aboul-Enein*

Journal Name: Coronaviruses
The World's First International Journal Dedicated to Coronaviruses

Article ID: e170821190015
Become EABM
Become Reviewer
Call for Editor


Hydroxychloroquine is a chloroquine derivative which is well recognized for its ‘SARS-CoV-2 or COVID-19’ & other uses. It’s one of the key drugs of malaria and other various respiratory diseases. The drug exhibits a wide range of activities that include strong antimalarial, antidibetic, anticancer, anti-HIV, antifungal, antimicrobial and antioxidant activities. The based on latest study of corona virus, they have showed five mutations or genetic change in their structure, due to change of their climatic condition (e. i. R 207C (nsp 2-27) – Wuhan (China), V 378 I (nsp 2- 198) – Italy, M 2796I (nsp 4- 33) – Iran, L 3606F (nsp 6- 37)-America and V 9082F (ORF 7a- 74) – Kuwait). Here is so many preclinical, clinical, theoretical and experimental evidence, All these supports are directly related to the effectiveness of HCQ & CQ on patients affected by COVID-19. Based on the evidence currently underway and future research, we will be able to provide better role results in COVID-19 transition of HCQ and CQ. It displays several activities that are related to the respiratory system and numerous studies have suggested that the compound may be beneficial to protect against disease such as malaria and lupus erythematosus. The present review represents the role & use of HCQ as a COVID-19 disease. The object for this review study is based on the research evidence obtained from different authentic sources and currently used for the treatment of HCQ and CQ in the corona virus and various other infections.

Keywords: HCQ, COVID-19, anti-HIV, anticancer, zika, respiratory diseases

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Article ID: e170821190015
Published on: 07 January, 2021
(E-pub Ahead of Print)
DOI: 10.2174/2666796701666210108115614

Article Metrics

PDF: 2